German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing ...

German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ...

(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

As well as the economic and employment benefits, BioNTech’s UK investment is expected to deliver tangible improvements in healthcare. The company’s work in personalised cancer immunotherapies, already ...

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.

Covid-19 vaccine pioneers BioNTech commit to up to £1 billion, 10-year investment in the UK. Covid-19 vaccine pioneers ...

Cambridge is set to become home to a major new research and development hub as part of a £1bn UK investment by biopharmaceutical firm BioNTech, expected to create more than 400 ...